Abstract 48: RBN-2397: A potent and selective small molecule...
RBN-2397 is the first agent to enter clinical trials that targets this tumor-intrinsic vulnerability, and a Phase I clinical trial is underway (NCT04053673).doi:10.1158/1538-7445.AM2021-48Joseph M. GozgitMelissa M. VasbinderRyan P. Abo...